Improving the treatment of Clostridium difficile-associated disease: Where should we start?

Clinical Infectious Diseases

Volumn 43, Issue 5, 2006, Pages 553-555

  Pepin, Jacques ^a,b  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE; NITAZOXANIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAMOPLANIN; RIFAMPICIN; RIFAXIMIN; VANCOMYCIN;

BACTERIAL INFECTION; BACTERIAL SPORE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE; DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; MORTALITY; NONHUMAN; NOTE; PRIORITY JOURNAL; RECURRENCE RISK; SYMPTOMATOLOGY; TREATMENT RESPONSE;

ANTI-BACTERIAL AGENTS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS;

EID: 33747599197     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/506357     Document Type: Note

References (29)

1. Bartlett JG. Antibiotic-associated diarrhea. N Engl J Med 2002; 346:334-9.
2. Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, Petit JC. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000; 38:2386-8.
3. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Québec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171:466-72.
4. Warny M, Pépin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366:1079-84.
5. McCannell DR, Louie TJ, Gregson DB, et al. Molecular analysis of Clostridium difficile ribotype 027 (NAP1) isolates from Eastern and Western Canada. J Clin Microbiol 2006; 44:2147-52.
6. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442-9.
7. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353:2433-41.
8. Health Protection Agency. Outbreak of Clostridium difficile infection in a hospital in south east England. CDR Wkly 2005; 15:2-3. Available at: http://www.hpa.org.uk/cdr/archives/2005/cdr2405.pdf. Accessed 16 July 2006.
9. Kuijper E, van den Berg R, Debast S, et al. Clostridium difficile ribotype 027, toxinotype III, The Netherlands. Emerg Infect Dis 2006; 12:827-30.
10. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006; 12:409-15.
11. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005; 173:1037-41.
12. Muto CA, Pokrywka M, Shutt K et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005; 26:273-80.
13. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Québec, Canada. Clin Infect Dis 2005; 40:1591-7.
14. Musher D, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40:1586-90.
15. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet 1983; 2:1043-6.
16. Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 22:813-8.
17. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97:1769-75.
18. Buggy BP, Fekety R, Silva J Jr. Therapy of Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin. J Clin Gastroenterol 1987; 9:155-9.
19. Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978; 3:108-27.
20. Bishara J, Bloch Y, Garty M, Behor J, Samra Z. Antimicrobial resistance of Clostridium difficile isolates in a tertiary medical center, Israel. Diagn Microbiol Infect Dis 2006; 54:141-4.
21. Bacon AE, McGrath S, Fekety R, Holloway WJ. In vitro synergy studies with Clostridiiim difficile. Antimicrob Agents Chemother 1991; 35:582-3.
22. Barbut F, Decré D, Burghoffer B, et al. Antimicrobial susceptibility and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrob Agents Chemother 1999; 43:2607-11.
23. Ensminger PW, Coutner FT, Thomas LJ, Lubbehusen PP. Susceptibility, resistance development, and synergy of antimicrobial combinations against Clostridium difficile. Curr Microbiol 1982; 7:59-62.
24. Lagrotteria D, Holmes S, Smieja M, Smail F, Lee C. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea (CDAD). Clin Infect Dis 2006; 43:547-52 (in this issue).
25. Pelaez T, Alcala L, Alonso R, et al. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. Antimicrob Agents Chemother 2005; 49:1157-9.
26. Marchese A, Salerno A, Pesce A, Debbia EA, Schito GC. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy 2000; 46:253-66.
27. McVay CS, Rolfe RD. In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob Agents Chemother 2000; 44:2254-8.
28. Adachi JA, DuPont HL. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin Infect Dis 2006; 42:541-7.
29. Braunlin W, Xu Q, Hook P, et al. Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea. Biophys J 2004; 87:534-9.